{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"17.8","value":"7.8"},{"groupId":"OG001","lowerLimit":"3.0","upperLimit":"9.7","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"description":"Defined as the time from the date of randomization to the date of documented disease progression.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat Progression Free Survival (ITT-PFS) Population: Includes the first 480 randomized participants in the ITT analysis population (evaluated by their random treatment assignment).","reportingStatus":"POSTED","timeFrame":"34.6 months","title":"Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)","type":"PRIMARY","unitOfMeasure":"months"}